Biogen seeks early-stage pipeline deals after $5.6 billion Apellis acquisition

Biogen announced it has earmarked $5.6 billion to acquire Apellis Pharmaceuticals, a move completed earlier this month.

Despite the large transaction, the company says it will continue to explore additional partnerships and acquisitions, focusing primarily on early-stage research and development assets.

Executives indicated that the strategy aims to broaden Biogen’s pipeline beyond its current portfolio, targeting novel therapeutic candidates that can be advanced through pre-clinical and early clinical phases.

The emphasis on early-stage deals reflects Biogen’s intent to diversify its product base and mitigate reliance on later-stage launches.